Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: a Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alpha-2b

J Clin Oncol. 2008 Mar 10;26(8):1316-1323, JC Yao, A Phan, PM Hoff, HX Chen, C Charnsangavej, SCJ Yeung, K Hess, C Ng, JL Abbruzzese, JA Ajani

ABSTRACT

NOT A MEMBER?

OncologySTAT registration is FREE and takes less than a minute to complete. Registration provides instant access to 100+ Elsevier cancer-related journals, journal scans, daily medical and regulatory news, professional drug and interactions databases, chemotherapy regimens, and InfoBLAST - OncologySTAT's weekly e-newsletter.

 

Editors' Choice

Palliative Care With Chemotherapy Extends Survival in Metastatic NSCLC
Read more ›

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.
Sign-up now  ›

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration